Literature DB >> 15123366

Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis.

Enrico Brunetti1, Enrico Silini, Angela Pistorio, Alessandra Cavallero, Anna Marangio, Raffaele Bruno, Carlo Filice.   

Abstract

BACKGROUND/AIMS: Liver biopsy is crucial in defining natural history and therapeutic choices in chronic hepatitis C and it is usually performed with coarse (>1 mm) needles (CN). As fine needles (FN) do not require anaesthesia, are used over a wider range of coagulation values and allow multiple passes, we compared the diagnostic yield of FN vs. CN biopsies.
METHODS: Paired samples obtained with FN (0.8 mm) and CN (1.2 mm) on 149 consecutive outpatients from a tertiary care institution were evaluated prospectively. Histologic variables were quantitatively scored. Sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio were calculated as measures of diagnostic ability assuming CN as reference.
RESULTS: FN biopsy was adequate in 83 cases, CN in 140 cases (P<0.001). Considering the 83 paired adequate specimens, the best sensitivity of FN vs. CN was for portal inflammation (0.95%) and the worst for cirrhosis (0.33%). Overall discriminant ability of FN was unsatisfactory and histologic variables were systematically underscored. Tolerability was good for both procedures.
CONCLUSIONS: The advantages of FN biopsy are lost on its inferior diagnostic performance. Its use in diffuse liver diseases should be restricted to early non-fibrotic lesions.

Entities:  

Mesh:

Year:  2004        PMID: 15123366     DOI: 10.1016/j.jhep.2003.11.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Liver fibrosis: natural history may be affected by the biopsy sample.

Authors:  M Guido; M Rugge
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 2.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 3.  The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.

Authors:  Mingjie Yao; Leijie Wang; Patrick S C Leung; Yanmei Li; Shuhong Liu; Lu Wang; Xiaodong Guo; Guangde Zhou; Ying Yan; Guiwen Guan; Xiangmei Chen; Christopher L Bowlus; Tianhui Liu; Jidong Jia; M Eric Gershwin; Xiong Ma; Jingmin Zhao; Fengmin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

4.  Routine ultrasound-guided liver biopsy versus echo-assisted procedure in viral chronic hepatitis.

Authors:  R Chiavaroli; P F Grima; P Calabrese; P Grima
Journal:  Radiol Med       Date:  2008-09-25       Impact factor: 3.469

5.  Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Authors:  Norah A Terrault; Kelly Im; Ross Boylan; Peter Bacchetti; David E Kleiner; Robert J Fontana; Jay H Hoofnagle; Steven H Belle
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

6.  Laparoscopic liver biopsy in the diagnosis of hepatic epithelioid hemangioendothelioma: A case report.

Authors:  Yilei Deng; Yong Zhou; Nansheng Cheng
Journal:  Oncol Lett       Date:  2014-07-02       Impact factor: 2.967

7.  Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries.

Authors:  Xiangjun Qian; Sujun Zheng; Leijie Wang; Mingjie Yao; Guiwen Guan; Xiajie Wen; Ling Zhang; Qiang Xu; Xiangmei Chen; Jingmin Zhao; Zhongping Duan; Fengmin Lu
Journal:  Dis Markers       Date:  2019-09-17       Impact factor: 3.434

8.  Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.

Authors:  James Neuberger; Jai Patel; Helen Caldwell; Susan Davies; Vanessa Hebditch; Coral Hollywood; Stefan Hubscher; Salil Karkhanis; Will Lester; Nicholas Roslund; Rebecca West; Judith I Wyatt; Mathis Heydtmann
Journal:  Gut       Date:  2020-05-28       Impact factor: 23.059

9.  Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis.

Authors:  Leijie Wang; Mingjie Yao; Shuhong Liu; Danli Yang; Xiajie Wen; Jing Ning; Lu Wang; Guangde Zhou; Qiang Xu; Xiangmei Chen; Jingmin Zhao; Fengmin Lu
Journal:  Dis Markers       Date:  2020-02-04       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.